

Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer

Xixi YING^{1,2,#}, Zheng SHI^{3,4,#}, Rongjun SHAO^{1,2,#}, Guangxian YOU^{2,*}, Zhengbo SONG^{1,3,4,*}

¹Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; ²Department of Radiology and Oncology, Taizhou Cancer Hospital, Taizhou, China; ³Postgraduate Training Base Alliance of Wenzhou Medical University, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; ⁴Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

*Correspondence: guangxianyou2000@163.com; songzb@zjcc.org.cn

Received October 14, 2024 / Accepted October 23, 2024

Due to the delayed delivery of the request for a correction and the requirement from the Office of Zhejiang Chinese Medical University to standardize the institution's English translation, the editorial department of NEOPLASMA has issued a correction in response to the author's signed request:

The affiliation of the first author has been changed from "Graduate School of Zhejiang University of Traditional Chinese Medicine" to "Graduate School, Zhejiang Chinese Medical University."

This corrects the article https://doi.org/10.4149/neo_2024_231104N572.

The original article has been updated.



Copyright © 2024 The Authors.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source and provide a link to the Creative Commons licence. To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>